Company profile
RepliCel Life Sciences Inc.
OTC: REPCF · Healthcare · Biotechnology
Canadian filerHQ Vancouver, BCCIK 0001205059Reports USD
#1 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 26
v0.1 · 5/100 weight · pillars only
↑ Piotroski F, listing tenure · ↓ workforce scale, filing timeliness
Methodology →Revenue TTM
$381.9k
Rev growth YoY (TTM)
+123.5%
Net income (FY)
-$571.2k
Employees
1
as of 2026-08-30
Market cap
$7.4k
as of 2026-08-30
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$571.2k-743.2k CAD2022
Total assets$589.4k798.2k CAD2022
Liabilities$5.0M6.7M CAD2022
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is RepliCel Life Sciences Inc.’s financial profile?
RepliCel Life Sciences Inc. earned -$571.2k in FY2022 net income.
Peers · Healthcare
HEALTHeUNIVERSE, Inc.——Green Hygienics, Inc.——ChromoCure, Inc.——MabCure Inc.——WOWI, Inc.——American Scientific Resources, Incorporated——Key facts
CEOAndrew Schutte
SectorHealthcare
IndustryBiotechnology
HeadquartersVancouver, BC
ExchangeOTC: REPCF
Employees1
IPO date2010-05-03
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.